Free Trial

Maxpro Capital Acquisition (JMAC) Competitors

Maxpro Capital Acquisition logo
$10.69 -0.11 (-1.02%)
As of 01/3/2025

JMAC vs. KOD, ALT, TRML, PROK, XERS, ATXS, CRMD, RNAC, TKNO, and TERN

Should you be buying Maxpro Capital Acquisition stock or one of its competitors? The main competitors of Maxpro Capital Acquisition include Kodiak Sciences (KOD), Altimmune (ALT), Tourmaline Bio (TRML), ProKidney (PROK), Xeris Biopharma (XERS), Astria Therapeutics (ATXS), CorMedix (CRMD), Cartesian Therapeutics (RNAC), Alpha Teknova (TKNO), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry.

Maxpro Capital Acquisition vs.

Kodiak Sciences (NASDAQ:KOD) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.

Kodiak Sciences received 19 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Kodiak SciencesOutperform Votes
19
27.54%
Underperform Votes
50
72.46%
Maxpro Capital AcquisitionN/AN/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$260.49M-$3.65-2.50
Maxpro Capital AcquisitionN/AN/AN/AN/AN/A

Kodiak Sciences presently has a consensus price target of $8.00, indicating a potential downside of 12.28%. Given Kodiak Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Kodiak Sciences is more favorable than Maxpro Capital Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Maxpro Capital Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Kodiak Sciences had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for Kodiak Sciences and 0 mentions for Maxpro Capital Acquisition. Kodiak Sciences' average media sentiment score of 0.25 beat Maxpro Capital Acquisition's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Overall Sentiment
Kodiak Sciences Neutral
Maxpro Capital Acquisition Neutral

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 45.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kodiak Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.

Maxpro Capital Acquisition's return on equity of 0.00% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -84.52% -45.40%
Maxpro Capital Acquisition N/A N/A N/A

Summary

Kodiak Sciences beats Maxpro Capital Acquisition on 9 of the 11 factors compared between the two stocks.

Get Maxpro Capital Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for JMAC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JMAC vs. The Competition

MetricMaxpro Capital AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ Exchange
Market Cap$143.55M$437.61M$119.59M$9.05B
Dividend YieldN/A6.65%5.15%4.19%
P/E RatioN/A2.191.1917.29
Price / SalesN/A121.811.17124.74
Price / CashN/A62.0880.6537.86
Price / BookN/A84.30519.875.19
Net IncomeN/A$34.28M$2.33M$226.98M
7 Day Performance8.20%26.62%30.20%3.14%
1 Month Performance2.49%28.44%29.81%5.49%
1 Year Performance1,144.47%27.42%24.08%21.67%

Maxpro Capital Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JMAC
Maxpro Capital Acquisition
N/A$10.69
-1.0%
N/A+1,019.4%$143.55MN/A0.002,021
KOD
Kodiak Sciences
2.9203 of 5 stars
$9.97
-0.1%
$8.00
-19.8%
+200.0%$524.66MN/A-2.7390
ALT
Altimmune
2.161 of 5 stars
$7.32
-4.6%
$20.00
+173.2%
-37.9%$520.64M$52,000.00-4.7250News Coverage
TRML
Tourmaline Bio
1.9004 of 5 stars
$20.08
-2.9%
$54.00
+168.9%
-19.4%$514.91MN/A-7.1244
PROK
ProKidney
2.2247 of 5 stars
$1.75
+2.6%
$4.50
+157.9%
+23.2%$508.95MN/A-3.173News Coverage
XERS
Xeris Biopharma
4.0129 of 5 stars
$3.38
-1.5%
$4.87
+44.0%
+42.7%$503.89M$187.36M-7.51290
ATXS
Astria Therapeutics
2.6564 of 5 stars
$8.88
-3.0%
$25.60
+188.3%
+26.5%$501.13MN/A-4.2530Positive News
CRMD
CorMedix
2.5259 of 5 stars
$8.10
-1.3%
$15.80
+95.1%
+135.7%$491.48M$12.26M-10.0030Positive News
RNAC
Cartesian Therapeutics
2.71 of 5 stars
$18.76
-5.2%
$42.86
+128.4%
-12.1%$476.79M$47.94M-0.3637
TKNO
Alpha Teknova
1.0312 of 5 stars
$8.85
+1.4%
$5.00
-43.5%
+129.2%$471.78M$36.35M-11.96240Positive News
Gap Up
TERN
Terns Pharmaceuticals
4.0158 of 5 stars
$5.53
-4.2%
$18.30
+230.9%
-14.2%$469.71M$1M-4.6940

Related Companies and Tools


This page (NASDAQ:JMAC) was last updated on 1/5/2025 by MarketBeat.com Staff
From Our Partners